(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today it has received a positive recommendation from the independent Data Monitoring Committee (DMC) to continue enrolling into the company's Phase 3 'DOM-INNATE' study (Dusquetide treatment in Oral
Mucositis by modulating INNATE immunity) for SGX942 (dusquetide) in the treatment of oral
mucositis in patients with head and neck cancer (HNC).
Soligenix has received a positive recommendation from the independent Data Monitoring Committee to continue enrolling into the company's Phase 3 "DOM-INNATE" study for SGX942 - dusquetide - in the treatment of oral
mucositis in patients with head and neck cancer.
earned another SBIR grant, this time banking $150,000 to advance its study of SGX942 for pediatric indications including oral
mucositis in patients with head and neck cancer.
MONDAY, July 22, 2019 (HealthDay News) -- Photobiomodulation (PBM), such as laser and other light therapies, is recommended for prevention of oral
mucositis (OM) in specific populations of cancer patients, according to a review published online July 8 in Supportive Care in Cancer.
Keywords: Stem cell transplantation, Oral
mucositis, Nursing.
Transfusion requirements, duration of hospitalization, and frequency and duration of adverse events, including fever, neutropenia, and
mucositis were evaluated during follow-up.
M2 EQUITYBITES-April 5, 2019-Soligenix expects US patent for Dusquetide related analogs in infectious disease and oral
mucositisGlobal Banking News-April 5, 2019-Soligenix expects US patent for Dusquetide related analogs in infectious disease and oral
mucositisM2 PHARMA-April 5, 2019-Soligenix expects US patent for Dusquetide related analogs in infectious disease and oral
mucositisOral
mucositis (OM) is a side effect related to radiation and cancer chemotherapy.
The Lite Therapy Effectiveness For Oral
Mucositis (LiTEFORM) trial will discover if low-level laser treatment can help in the management of painful irritation of the mouth lining - a common and very unpleasant side effect of chemotherapy and radiotherapy.
LiTEFORM will tell doctors whether low-level laser therapy reduces the burden of painful
mucositis for patients.